HC Wainwright & Co. Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $1201

Benzinga Newsdesk www.benzinga.com Negative 59.2%

Neg 59.2% Neu 0% Pos 0%

HC Wainwright & Co. analyst Douglas Tsao maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and lowers the price target from $1245 to $1201.